Literature DB >> 820994

Pharmacologic closure of patent ductus arteriosus in the premature infant.

W F Friedman, M J Hirschklau, M P Printz, P T Pitlick, S E Kirkpatrick.   

Abstract

The prostaglandins affect smooth-muscle tone of the ductus arteriosus. Patent ductus often complicates the clinical course of prematurely born infants with respiratory-distress syndrome. In the present study, a single oral or rectal dose of a potent inhibitor of prostaglandin synthesis, indomethacin, was administered to six consecutive premature infants with the syndrome who would otherwise have undergone surgical ligation of the patent ductus. Within 24 hours all the clinical symptoms and physical, echocardiographic and radiographic signs attributable to substantial left-to-right shunting through a patent ductus arteriosus dramatically and permanently disappeared. A transient reduction in renal function was observed in two infants in whom sustained ill-effects did not occur. The observation that constriction and closure of the patent ductus arteriosus may be induced pharmacologically raises important possibilities for the improved treatment of the respiratory-distress syndrome.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 820994     DOI: 10.1056/NEJM197609022951003

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  85 in total

1.  Clinical profile and management of PDA in neonates.

Authors:  C C Shanthala; P P Maiya; D Vishwanath; N Banakappa; P M Swamy; N Desai; K H Srinivas
Journal:  Indian J Pediatr       Date:  1997 Sep-Oct       Impact factor: 1.967

2.  Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.

Authors:  Arne Ohlsson; Sachin S Shah
Journal:  Cochrane Database Syst Rev       Date:  2019-06-21

3.  Results from extrapleural clipping of a patent ductus arteriosus in seriously ill preterm infants.

Authors:  Orhan Demirturk; Murat Güvener; Isa Coşkun; Hüseyin Ali Tünel
Journal:  Pediatr Cardiol       Date:  2011-07-14       Impact factor: 1.655

4.  Comparative effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus.

Authors:  Brian C Gulack; Matthew M Laughon; Reese H Clark; Meera N Sankar; Christoph P Hornik; P Brian Smith
Journal:  Early Hum Dev       Date:  2015-09-19       Impact factor: 2.079

5.  Failure of indomethacin to close persistent ductus arteriosus in infants weighing under 1000 grams.

Authors:  H H Ivey; J Kattwinkel; T S Park; L J Krovetz
Journal:  Br Heart J       Date:  1979-03

6.  Persistent ductus arteriosus complicating the respiratory distress syndrome.

Authors:  R W Jones; D Pickering
Journal:  Arch Dis Child       Date:  1977-04       Impact factor: 3.791

7.  Ibuprofen in very preterm infants impairs renal function for the first month of life.

Authors:  Rachel Vieux; Roxane Desandes; Farid Boubred; Denis Semama; Francis Guillemin; Marie-Christine Buchweiller; Jeanne Fresson; Jean-Michel Hascoet
Journal:  Pediatr Nephrol       Date:  2009-11-10       Impact factor: 3.714

8.  Association between prophylactic indomethacin and death or bronchopulmonary dysplasia: A systematic review and meta-analysis of observational studies.

Authors:  Erik A Jensen; Elizabeth E Foglia; Barbara Schmidt
Journal:  Semin Perinatol       Date:  2018-05-10       Impact factor: 3.300

9.  Platelets contribute to postnatal occlusion of the ductus arteriosus.

Authors:  Katrin Echtler; Konstantin Stark; Michael Lorenz; Sandra Kerstan; Axel Walch; Luise Jennen; Martina Rudelius; Stefan Seidl; Elisabeth Kremmer; Nikla R Emambokus; Marie-Luise von Bruehl; Jon Frampton; Berend Isermann; Orsolya Genzel-Boroviczény; Christian Schreiber; Julinda Mehilli; Adnan Kastrati; Markus Schwaiger; Ramesh A Shivdasani; Steffen Massberg
Journal:  Nat Med       Date:  2009-12-06       Impact factor: 53.440

10.  Intravenous indometacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic study.

Authors:  J M Smyth; P S Collier; M Darwish; J S Millership; H L Halliday; S Petersen; J C McElnay
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.